Show simple item record

dc.contributor.advisorEkpo, Okobi
dc.contributor.authorDelport, Joshua
dc.date.accessioned2023-11-14T07:37:13Z
dc.date.available2023-11-14T07:37:13Z
dc.date.issued2023
dc.identifier.urihttp://hdl.handle.net/11394/10545
dc.description>Magister Scientiae - MScen_US
dc.description.abstractParkinson’s disease (PD) is the second most common age-related neurodegenerative disease after Alzheimer’s disease, with an estimated 9 million people projected to be affected worldwide by the year 2030. PD is associated with numerous motor symptoms such as tremor, bradykinesia (slowness of movements), hypokinesia (reduction in movement amplitude) and akinesia (absence of normal unconscious movements). However, in addition to these motor symptoms, several nonmotor manifestations are common, such as sensory symptoms (pain, tingling), hyposmia, sleep disturbance, depression, and cognitive impairment.en_US
dc.language.isoenen_US
dc.publisherUniversity of the Western Capeen_US
dc.subjectPhyllanthinen_US
dc.subjectSH-SY5Yen_US
dc.subjectMPP+en_US
dc.subjectParkinson’s Diseaseen_US
dc.subjectNeuroprotectionen_US
dc.titleIn vitro neuroprotective potential of phyllanthin in MPP+- induced toxicity in SH-SY5Y neuroblastoma cellsen_US
dc.rights.holderUniversity of the Western Capeen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record